Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2+ Advanced Gastroesophageal Adenocarcinoma
NCT06043427Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in gastroesophageal adenocarcinoma, sponsored by Canadian Cancer Trials Group. Started Apr 2024; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT06043427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043427.